

SeQuent Scientific Limited (Consolidated)
ANNEXURE B

The financial details of companies for the previous 3 years as per the audited statement of Accounts:

(Rs. In Crores)

Particulars	Note	June' 24 Special Purpose Interim Financial Information	As per last Audited Financial Year	1 year prior to the last Audited Financial Year	2 years prior to the last Audited Financial Year (Restated)
Equity Paid up Capital		49.90	49.89	49.89	49.67
Reserves and surplus	1	603.15	606.67	648.89	642.42
Carry forward losses		-	-	-	-
Net Worth	2	714.46	712.96	749.19	740.10
Miscellaneous Expenditure		-	-	-	-
Secured Loans		374.66	356.30	287.96	230.85
Unsecured Loans		74.02	94.98	109.93	84.04
Fixed Assets	3	256.69	259.70	284.60	229.77
Income from Operations		390.21	1,369.73	1,420.91	1,412.82
Total Income		392.89	1,380.69	1,427.30	1,423.66
Total Expenditure	4	380.89	1,435.33	1,564.96	1,370.73
Profit before Tax		12.00	(54.65)	(137.66)	52.93
Profit after Tax	5	9.06	(29.61)	(121.98)	44.76
Cash profit	6	28.25	6.89	(81.96)	104.47
EPS		0.26	(1.44)	(4.88)	1.65
Book value	7	28.64	28.58	30.04	29.80

Notes:

- Reserves & Surplus includes balances of all reserves excluding amount payable to minority interest shareholders.
- These are inclusive of Equity Paid up Capital and Reserves and Surplus including amount payable to minority interest shareholders.
- Fixed Assets include, Tangible property plant & equipments and CWIP.
- These include expenses of Exceptional nature recognized in books of accounts
- These numbers are exclusive of "Other Comprehensive Income".
- These are derived as: Profit before Tax + Depreciation and Amortization expenses.
- These are derived based on the Net worth of the Company and shares outstanding at the end of respective financial year /period.

SeQuent Scientific Limited

Registered Office: 301, 3rd Floor, Dosti Pinnacle, Plot No. E7, Road No. 22, Wagle Industrial Estate, Thane (W), Mumbai - 400604, Maharashtra India

Tel No.: +91-22-4111-4777 | CIN: L99999MH1985PLC036685

Website: <http://www.sequent.in> | Email Id: investorrelations@sequent.in

SeQuent Scientific Limited (Standalone)
ANNEXURE B

The financial details of companies for the previous 3 years as per the audited statement of Accounts:

(Rs. In Crores)					
Particulars	Note No.	June' 24 Special Purpose Interim Financial Information	As per last Audited Financial Year	1 year prior to the last Audited Financial Year	2 years prior to the last Audited Financial Year
Equity Paid up Capital		49.90	49.89	49.89	49.67
Reserves and surplus		1,046.53	1,037.34	1,008.48	991.41
Carry forward losses		-	-	-	-
Net Worth		1,096.43	1,087.23	1,058.36	1,041.09
Miscellaneous Expenditure		-	-	-	-
Secured Loans		26.69	46.46	19.10	15.50
Unsecured Loans		-	-	-	-
Fixed Assets	1	41.72	40.38	47.32	45.49
Income from Operations		57.67	168.52	222.69	219.63
Total Income		68.51	214.50	250.93	247.27
Total Expenditure	2	62.46	214.74	260.67	231.58
Profit before Tax		6.05	-0.24	-9.75	15.69
Profit after Tax	3	4.50	0.62	-6.08	14.80
Cash profit	4	8.05	8.70	-0.63	25.28
EPS		0.18	0.03	-0.24	0.60
Book value	5	43.95	43.59	42.43	41.92

Note:

1. Fixed assets include Tangible Property plant & equipments and CWIP.
2. Total expenditure includes exceptional items.
3. Profit after Tax is before consideration of "Other Comprehensive Income".
4. Cash profit is Profit before Tax + Depreciation and Amortization expenses.
5. Book Value is derived based on the Net worth of the Company and shares outstanding at the end of respective financial year /period.

SeQuent Scientific Limited

Registered Office: 301, 3rd Floor, Dosti Pinnacle, Plot No. E7, Road No. 22, Wagle Industrial Estate, Thane (W), Mumbai - 400604, Maharashtra India

Tel No.: +91-22-4111-4777 | CIN: L99999MH1985PLC036685

Website: <http://www.sequent.in> | Email Id: investorrelations@sequent.in



SeQuent Research Limited
ANNEXURE B

The financial details of companies for June 24 and previous 3 years as per the audited statement of Accounts:

(Rs. In Crores)

Particulars	Note	June' 24 Special Purpose Interim Financial Information	As per last Audited Financial Year	1 year prior to the last Audited Financial Year	2 years prior to the last Audited Financial Year
Equity Paid up Capital		4.41	4.41	4.41	4.41
Reserves and surplus		1.20	1.96	3.05	4.50
Carry forward losses		-	-	-	-
Net Worth		5.61	6.37	7.46	8.91
Miscellaneous Expenditure		-	-	-	-
Secured Loans		-	9.37	-	-
Unsecured Loans		-	-	-	-
Fixed Assets	1	1.16	1.31	2.14	3.00
Income from Operations		1.71	8.82	9.05	14.66
Total Income		1.92	9.88	9.54	14.91
Total Expenditure		2.72	11.59	10.93	11.28
Profit before Tax		-0.79	-1.71	-1.39	3.63
Profit after Tax	2	-0.60	-1.29	-1.44	2.73
Cash profit	3	-0.54	-0.48	0.06	5.18
EPS		-1.35	-2.92	-3.27	6.19
Book value	4	12.73	14.43	16.92	20.21

Notes:

1. Fixed assets include Property plant & equipments and CWIP.
2. Profit after Tax is before consideration of "Other Comprehensive Income".
3. Cash profit is Profit before Tax + Depreciation and Amortization expenses.
4. Book Value is derived based on the Net worth of the Company and shares outstanding at the end of respective financial year /period.

SeQuent Research Limited

Registered Office: 120/A&B, Industrial Area, Baikampady, Managlore – 575 011, Karnataka, India

Tel No: +91-824-2402-100 | CIN: U2432KA2007PLC042483

Website: <http://www.sequent.in> | Email Id: investorrelations@sequent.in

Corporate Office: 301, 3rd Floor, Dosti Pinnacle, Plot No. E7, Road No. 22, Wagle Industrial Estate, Thane (W), Mumbai - 400604, Maharashtra India

The financial details of companies for the previous 3 years as per the audited statement of Accounts:

ANNEXURE B

Name of the Company: Viyash Life Sciences Private Limited (Standalone) (Rs. in Crores)				
Particulars	As per last Audited financial statement for the quarter ended 30 June 2024	As per last Audited Financial Year (FY 2023 24)	1 year prior to the last Audited Financial Year (FY 2022-23)	2 years prior to the last Audited Financial Year (FY 2021-22)
Equity Paid up Capital	264.91	264.91	255.86	65.18
Reserves and surplus (including equity component of compound financial instruments and excluding carry forward losses)**	1,675.22	1,671.68	1,673.83	1,856.84
Carry forward losses	(124.32)	(115.72)	(97.23)	(43.46)
Net Worth #	1,815.80	1,820.86	1,832.46	1,878.55
Miscellaneous Expenditure	-	-	-	-
Secured Loans	54.46	57.55	69.29	53.03
Unsecured Loans	-	-	-	-
Fixed Assets*	170.08	172.09	179.30	134.27
Income from Operations	36.38	183.99	170.22	70.34
Total Income	37.72	190.37	179.24	79.19
Total Expenditure (including exceptional items)##	47.03	209.03	232.51	123.68
Profit before Tax	(9.31)	(18.66)	(53.27)	(44.49)
Profit after Tax	(9.13)	(18.62)	(53.40)	(39.19)
Cash profit###	(5.09)	(0.45)	(38.72)	(38.05)
EPS (Rs.)	(0.36)	(0.73)	(2.08)	(2.13)
Book value per share (Rs.)***	70.80	70.99	71.45	102.29

Notes:

* Fixed asset comprises of Property, plant and equipment and capital work in progress.

** Reserves and surplus includes instruments entirely equity in nature (FY 2022-23: Rs. 81.40 Crores, FY 2021-22: 342.58 Crores).

Net-worth includes equity share capital and Reserves and surplus (including equity component of compound financial instruments and excluding carry forward # losses), and carry-forward losses.

Total expenditure includes exceptional items related to impairment of investment, trade receivable, loans and advances and accrued interest (FY 2024-25(Q1): Rs. (0.34) Crores, FY 2023-24: 2.65 Crores and FY 2022-23: 26.30 Crores).

Cash profit = Profit before tax plus depreciation and amortization.

*** Book value per share is computed as networth divided by number of shares outstanding.

For Viyash Life Sciences Private Limited



Authorized Signatory


R&D CENTRE:

Plot No.80&81, Sy.No. 342
Aleap Industrial Estate, Pragathi Nagar,
Quthbullapur(M) Medchal-Malkajgiri District
Telangana 500 090, India. T: +91 93911 93386

Manufacturing Unit - I:

Plot No. 1-A/2 And 1-A/3,
MIDC, Industrial Area,
Taloja, Panvel, Raigarh - 410208.
Maharashtra, India. T : +91 22623 45515

Manufacturing Unit - II:

Plot No. 28, Sy. No. 1,3,9 & 26, Thanam Village
Parawada Mandal, Visakhapatnam District,
Andhrapradesh-531019, India
T: +91 98481 92205

ANNEXURE B
The financial details of companies for the previous 3 years as per the audited statement of Accounts:
Name of the Company: Viyash Life Sciences Private Limited (Consolidated)
(Rs. in Crores)

Particulars	As per last Audited financial statement	As per last Audited Financial Year (FY 2023-24)	1 year prior to the last Audited Financial Year	2 years prior to the last Audited Financial Year (FY 2021-22)
Equity Paid up Capital	264.91	264.91	255.86	65.18
Reserves and surplus (including equity component of compound financial instruments and excluding carry forward losses)**	1,695.67	1,690.45	1,685.80	1,861.36
Carry forward losses	(578.59)	(575.54)	(551.81)	(408.49)
Net Worth#	1,453.62	1,454.63	1,463.75	1,614.01
Miscellaneous Expenditure	-	-	-	-
Secured Loans	228.58	295.63	266.73	202.37
Unsecured Loans	-	11.06	45.30	46.34
Fixed Assets*	817.53	827.77	876.26	844.85
Income from Operations	339.99	1,310.99	1,207.51	912.88
Total Income	343.53	1,364.63	1,222.45	925.47
Total Expenditure (including exceptional items)##	337.90	1,364.30	1,427.39	1,059.49
Profit before Tax	5.63	0.33	(204.94)	(134.02)
Profit after Tax	(1.16)	(8.51)	(170.04)	(136.42)
Cash profit###	46.91	165.64	(33.37)	(35.36)
EPS (Rs.)	(0.07)	(0.51)	(5.20)	(6.40)
Book value per share (Rs.)***	56.68	56.72	57.07	87.89

Notes:

Fixed asset comprises of Property, plant and equipment and capital work in progress.

Reserves and surplus includes equity component of compound financial instruments (FY 2022-23: Rs. 81.40 Crores, FY 2021-22: 342.58 Crores).

Net-worth includes equity share capital, Reserves and surplus (including equity component of compound financial instruments and excluding carry forward losses), carry-forward losses and non-controlling interests.

Total expenditure includes exceptional items related to impairment of goodwill of (FY2022-23:Rs.6.21 Crs).

Cash profit = Profit before tax plus depreciation and amortization.

Book value per share is computed as networth divided by number of shares outstanding.

For Viyash Life Sciences Private Limited



Authorized Signatory


R&D CENTRE:

Plot No.80&81, Sy.No. 342
Aleap Industrial Estate, Pragathi Nagar,
Outhbullapur(M) Medchal-Malkajgiri District
Telangana 500 090, India. T: +91 93911 93386

Manufacturing Unit - I:

Plot No. 1-A/2 And 1-A/3,
MIDC, Industrial Area,
Taloja, Panvel, Raigarh - 410208.
Maharashtra, India. T : +91 22623 45515

Manufacturing Unit - II:

Plot No. 28, Sy. No. 1,3,9 & 26, Thanam Village
Parawada Mandal, Visakhapatnam District,
Andhrapradesh-531019, India.
T: +91 98481 92205

ANNEXURE -B

The financial details of companies for the previous 3 years as per the audited statement of Accounts:

Name of the Company: Appcure Lab Private Limited

(Rs in Crores)

Particulars	As per last Audited Financial statements for the quarter ended 30 June 2024	As per last Audited Financial Year (FY 2023-24)	1 year prior to the last Audited Financial Year (FY 2022-23)	2 years prior to the last Audited Financial Year (FY 2021-22)
Equity Paid up Capital	0.52	0.52	0.52	0.52
Reserves and surplus	5.84	4.53	4.16	3.77
Carry forward losses	-	-	-	-
Net Worth	6.36	5.05	4.68	4.29
Miscellaneous Expenditure	-	-	-	-
Secured Loans	-	-	-	-
Unsecured Loans	-	-	-	-
Fixed Assets ##	1.69	1.78	1.76	2.24
Income from Operations	5.48	16.30	10.58	11.14
Total Income	5.48	16.37	10.61	11.16
Total Expenditure	3.94	15.29	10.01	9.42
Profit/(Loss) before Tax	1.54	1.09	0.60	1.74
Profit/(Loss) after Tax	1.18	0.48	0.34	1.11
Depreciation	0.27	1.08	0.78	1.15
Cash profit/(Loss) **	1.45	1.55	1.13	2.26
EPS (Rs)	25.21	7.12	7.64	32.78
No of Shares	5,18,000	5,18,000	5,18,000	5,18,000
Book value (Rs.)	122.74	97.45	90.31	82.78

Fixed Assets comprises of Property, Plant and Equipment .

** Cash profit = Profit before tax plus depreciation.

For Appcure Lab Private Limited


Authorised Signatory



GENINN LIFE SCIENCES PRIVATE LIMITED
PLOT NO. 3, 4 & 5, ANRICH INDUSTRIAL ESTATE
BOLLARAM, HYDERABAD
MEDAK TELANGANA-502325
CIN: U24299TG2019PTC136520

ANNEXURE-B

The financial details of companies for the previous 3 years as per the audited statement of Accounts:

Name of the Company: Geninn Life Sciences Private Limited

Rs in Crores

Particulars	As per last Audited Financial statements for the quarter ended 30 June 2024	As per last Audited Financial Year (FY 2023-24)	1 year prior to the last Audited Financial Year (FY 2022-23)	2 years prior to the last Audited Financial Year (FY 2021-22)
Equity Paid up Capital	0.10	0.10	0.10	0.10
Reserves and surplus	0.10	0.04	(0.00)	(0.01)
Carry forward losses	-	-	-	-
Net Worth	0.20	0.14	0.10	0.09
Miscellaneous Expenditure	-	-	-	-
Secured Loans	-	-	-	-
Unsecured Loans	-	-	-	-
Fixed Assets	-	-	-	-
Income from Operations	-	-	-	-
Total Income	0.08	0.13	0.07	0.05
Total Expenditure	0.01	0.07	0.05	0.05
Profit before Tax	0.07	0.06	0.02	0.01
Profit after Tax	0.05	0.05	0.01	-
Cash profit	0.07	0.06	0.02	0.01
EPS	10.86	9.06	1.82	1.56
Book value per share	19.76	14.33	9.80	8.89

For Geninn Life Sciences Private Limited

[Handwritten Signature]

Authorised Signatory



ANNEXURE -B

The financial details of companies for the previous 3 years as per the audited statement of Accounts:

Name of the Company: S.V. Labs Private Limited

(Rs in Crores)

Particulars	As per last Audited Financial statements for the quarter ended 30 June 2024	As per last Audited Financial Year (FY 2023-24)	1 year prior to the last Audited Financial Year (FY 2022-23)	2 years prior to the last Audited Financial Year (FY 2021-22)
Equity Paid up Capital	6.04	6.04	6.04	6.04
Reserves and surplus	0.10	0.10	0.10	0.10
Carry forward losses	(63.74)	(60.07)	(44.13)	(2.53)
Net Worth	(57.61)	(53.93)	(37.99)	3.61
Miscellaneous Expenditure	-	-	-	-
Secured Loans	34.06	28.92	18.18	42.58
Unsecured Loans	24.34	26.05	62.82	54.19
Fixed Assets ##	33.00	33.63	34.51	32.66
Income from Operations	41.32	161.66	199.55	254.83
Total Income	41.49	162.47	199.87	256.38
Total Expenditure @@	45.16	178.39	241.47	273.74
Profit/(Loss) before Tax	(3.67)	(15.92)	(41.59)	(17.36)
Profit/(Loss) after Tax	(3.67)	15.92	(41.59)	(17.36)
Depreciation	1.14	5.06	4.91	4.30
Cash profit/(Loss) **	(2.53)	20.99	(36.69)	(13.06)
EPS (Rs)	(6.08)	(26.39)	(68.89)	(26.57)
Book value (Rs.)	(95.40)	(89.30)	(62.91)	5.97

Fixed Assets comprises of Property, Plant and Equipment and Capital work in Progress.

** Cash profit = Profit before tax plus depreciation.

@@ Total Expenditure inclusive of Exceptional (Income/Expenditure) Rs. 0.1 Cr(Q1'25), Rs.-3.82 Crs (FY'24) and Rs.15.43 Cr(FY'23)

For S.V.Labs Private Limited



Authorised Signatory



SV LABS PRIVATE LIMITED
(CIN No: U24239AP2003PTC041662)

SYMED LABS LIMITED

Plot No. 290, Srivalli's Corporate, Road No.6, Kakatiya Hills,
Madhapur, Hyderabad-500 081, Telangana, India
URL : <http://www.symedlabs.com>, CIN No. U24231TG1998PLC029961

ANNEXURE-B

The financial details of companies for the previous 3 years as per the audited statement of Accounts:

Name of the Company: Symed Labs Limited

Rs in Crores

Particulars	As per last Audited Financial statements for the quarter ended 30 June 2024	As per last Audited Financial Year (FY 2023-24)	1 year prior to the last Audited Financial Year (FY 2022-23)	2 years prior to the last Audited Financial Year (FY 2021-22)
Equity Paid up Capital	0.93	0.93	0.93	0.93
Reserves and surplus	629.56	600.54	499.94	470.79
Carry forward losses	-	-	-	-
Net Worth \$\$	630.49	601.47	500.87	471.72
Miscellaneous Expenditure	-	-	-	-
Secured Loans	63.06	105.84	78.84	-
Unsecured Loans	-	-	-	-
PPE	311.55	310.88	305.57	278.24
CWIP	0.20	0.97	5.25	10.67
Fixed Assets ^^	311.75	311.84	310.83	288.91
Income from Operations	171.27	708.70	621.79	481.99
Total Income	172.74	745.47	630.95	490.02
Total Expenditure @@	134.65	606.85	568.84	455.79
Profit before Tax	38.09	138.75	43.82	34.23
Profit after Tax	28.31	100.81	28.91	22.11
Cash profit **	43.59	159.49	67.37	52.11
EPS (Rs.)	304.40	1,081.58	313.43	229.02
Book value Per Share (Rs.)%%	6,778.72	6,466.72	5,385.14	5,071.70

^^Fixed asset comprises of Property, plant and equipment and capital work in progress.

\$\$ Net-worth includes equity share capital, Reserves and surplus

@@ Total expenditure includes exceptional items of provision for trade receivables 18.29cr for FY 23.

**Cash profit = Profit before tax plus depreciation and amortization.

%%Book value per share is computed as networth divided by number of shares outstanding.

For Symed Labs Limited


Authorised Signatory



Registered Office Address : Plot No.290, Srivalli's Corporate, Road No.6, Kakatiya Hills, Madhapur, Hyderabad-500081, Telangana, India.
Unit-I : Survey No. 353, Domadugu (Village), Gummadidala (Mandal), Sangareddi-502313, Telangana, India, Tel: +91-40-23635052
Unit-II : Plot No. 25/B, Phase-III, IDA, Jeedimetla, Quthbullapur, Medchal-Malkajgiri-500055, Telangana, India, Tel: +91-40-23191337
Unit-IV : Survey No. 163, 163/A, 164/A, Pittampally, Chityal, Nalgonda-508114, Telangana, India, Tel: +91-40-23635090
Unit-VI : Survey No. 744,745, 750, 751, 752 &753, Mandollagidem, Choutuppal, Yadadri-508252, Telangana, India, Tel: +91-40-23635097.
Unit-V & R&D : Plot No. 89/A, Phase-1, IDA, Jeedimetla, Quthbullapur, Medchal, Malkajgiri-500055, Telangana, India, Tel: +91-40-23635097

ANNEXURE -B

The financial details of companies for the previous 3 years as per the audited statement of Accounts:

Name of the Company: Vandana Life Sciences Private Limited

(Rs in Crores)

Particulars	As per last Audited Financial statements for the quarter ended 30 June 2024	As per last Audited Financial Year (FY 2023-24)	1 year prior to the last Audited Financial Year (FY 2022-23)	2 years prior to the last Audited Financial Year (FY 2021-22)
Equity Paid up Capital	1.86	1.86	1.86	1.86
Reserves and surplus	1.34	1.34	1.34	1.34
Carry forward losses	(107.00)	(104.66)	(91.03)	(65.55)
Net Worth	(103.81)	(101.47)	(87.84)	(62.36)
Miscellaneous Expenditure	-	-	-	-
Secured Loans	38.43	40.09	18.95	20.35
Unsecured Loans	49.95	48.76	73.25	86.49
Fixed Assets ##	-	-	33.40	35.38
Income from Operations	0.50	5.58	90.22	94.21
Total Income	0.57	6.18	90.69	94.62
Total Expenditure	2.90	19.81	116.17	127.54
Profit/(Loss) before Tax	(2.33)	(13.63)	(25.49)	(32.92)
Profit/(Loss) after Tax	(2.33)	(13.63)	(25.49)	(31.56)
Cash profit/(Loss) **	(2.33)	(9.62)	(20.51)	(26.52)
EPS (Rs)	(12.59)	(73.47)	(137.39)	(169.99)
Book value (Rs.)	(559.60)	(547.01)	(473.54)	(336.15)

Fixed Assets comprises of Property, Plant and Equipment and Capital work in Progress.

** Cash profit = Profit before tax plus depreciation.

For Vandana Life Sciences Private Limited




Authorised Signatory

VANDANA LIFE SCIENCES PRIVATE LIMITED
(CIN: U24239TG2002PTC040132)

Factory : Plot No. 6, Road No.12, Sy No. 138,139,156 & 161, Tadi Village, JNPC, Parwada Mandal, Visakhapatnam District, Andhra Pradesh State, India-531 019. Ph : 089-24236558

Corporate Office : Plot No. 290, Street No.6, Ayyana pride, Kakathiya Hills, Madhapur - 500081, Hyderabad, Telangana
Phone : 040-64565626 E-mail : dnvandanalifesciences@gmail.com

ANNEXURE-I

The financial details of companies for the previous 3 years as per the audited statement of Accounts:

Name of the Company: Vindhya Organics Private Limited

Rs in Crores

Particulars	As per last Audited Financial statements for the quarter ended 30 June 2024	As per last Audited Financial Year (FY 2023-24)	1 year prior to the last Audited Financial Year (FY 2022-23)	2 years prior to the last Audited Financial Year (FY 2021-22)
Equity Paid up Capital	4.06	4.06	4.06	4.06
Reserves and surplus	22.22	20.23	12.90	32.06
Carry forward losses	-	-	-	-
Net Worth	26.28	24.29	16.95	36.12
Miscellaneous Expenditure	-	-	-	-
Secured Loans	3.81	2.28	20.13	32.28
Unsecured Loans	-	9.35	23.33	-
Fixed Assets ##	35.45	39.36	39.61	24.60
Income from Operations	46.01	168.67	148.07	174.23
Total Income	46.06	185.76	149.61	175.87
Total Expenditure @@	42.49	176.38	168.44	188.48
Profit before Tax	3.58	9.38	(18.84)	(12.61)
Profit after Tax	1.93	7.35	(18.92)	(11.63)
Cash profit **	2.43	9.45	(17.22)	(10.16)
EPS	4.75	18.07	(47.24)	(28.61)
Book value	64.77	59.86	41.78	89.02

@@ Total expenditure includes Exceptional items Rs. 2.89Cr (Q1'25), Rs.17.77 Cr (FY24), Rs.16.27 Cr (FY23) and Rs.Nil (FY22)

Fixed Assets comprises of Property, Plant and Equipment and Capital Work in Progress

** Cash profit = Profit before tax plus depreciation & amortisation

For Vindhya Organics Private Limited



 Authorised Signatory

VINDHYA ORGANICS PRIVATE LIMITED
 (CIN No: U24110TG1988PTC008252)

ANNEXURE -B

The financial details of companies for the previous 3 years as per the audited statement of Accounts:

Name of the Company: Vindhya Pharma (India) Private Limited

Rs in Crores

Particulars	As per last Audited Financial statements for the quarter ended 30 June 2024	As per last Audited Financial Year (FY 2023-24)	1 year prior to the last Audited Financial Year (FY 2022-23)	2 years prior to the last Audited Financial Year (FY 2021-22)
Equity Paid up Capital	1.87	1.87	1.87	1.87
Reserves and surplus	56.86	57.01	56.33	64.16
Carry forward losses	-	-	-	-
Net Worth	58.73	58.88	58.20	66.03
Miscellaneous Expenditure	-	-	-	-
Secured Loans	-	0.23	6.52	6.75
Unsecured Loans	8.51	8.51	15.51	20.33
Fixed Assets ##	0.06	0.06	2.31	6.89
Income from Operations	1.00	11.04	29.87	97.86
Total Income	1.12	13.85	30.93	151.78
Total Expenditure @@	1.27	13.18	38.97	91.39
Profit before Tax	(0.14)	0.67	(8.04)	60.39
Profit after Tax	(0.14)	0.67	(7.83)	46.69
Cash profit **	(0.14)	0.79	(6.74)	47.80
EPS (Rs.)	(0.76)	3.60	(41.87)	249.66
Book value(Rs.)	314.08	314.84	311.25	353.12

@@ Total expenditure includes Exceptional items Rs. 0.16Cr (Q1'25), Rs.0.9 Cr (FY24), Rs.2.26 Cr (FY23) and Rs.Nil (FY22)

Fixed Assets comprises of Property, Plant and Equipment and Capital Work in Progress

** Cash profit = Profit before tax plus depreciation & amortisation

For Vindhya Pharma (India) Private Limited



Authorised Signatory



VINDHYA PHARMA (INDIA) PRIVATE LIMITED
(CIN No: U24296TG2006PTC050700)